文献速递心律失常

CABANA试验:种族与族裔少数群体中房颤导管消融与药物治疗的比较

Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

CABANA试验纳入北美1280例症状性房颤患者,其中127例(9.9%)为种族/族裔少数群体,随机接受导管消融或药物治疗。少数群体中消融组主要终点事件风险降低68%(aHR 0.32,95%CI 0.13-0.78),全因死亡风险降低72%(aHR 0.28,95%CI 0.10-0.79),该获益在非少数群体中未见,可能源于少数群体药物治疗结局更差。

要点

  • 种族/族裔少数群体房颤患者接受导管消融较药物治疗主要终点风险降低68%。
  • 少数群体中消融组全因死亡风险降低72%,非少数群体未见此获益。
  • 少数群体药物治疗4年事件率27.4%,远高于非少数群体的9.4%。

核心结论

  • 在北美CABANA队列的种族或族裔少数群体中,导管消融较药物治疗显著改善主要临床结局。
  • 该获益未在非少数群体中观察到,可能归因于少数群体药物治疗结局更差。

研究设计与样本

  • CABANA试验随机分配2204例症状性房颤患者至导管消融或包含率/节律控制药物的药物治疗。
  • 本分析仅纳入北美入组的1280例参与者,按NIH定义分为种族/族裔少数群体(127例,9.9%)与非少数群体。

主要发现

  • 少数群体较非少数群体更年轻(中位年龄65.6岁 vs 68.5岁),症状性心衰(37.0% vs 22.0%)、高血压(92.1% vs 76.8%)及射血分数<40%(20.8% vs 7.1%)比例更高。
  • 少数群体消融组主要终点相对降低68%(aHR 0.32,95%CI 0.13-0.78),全因死亡相对降低72%(aHR 0.28,95%CI 0.10-0.79)。
  • 消融组4年Kaplan-Meier主要事件率在少数群体与非少数群体中相近(12.3% vs 9.9%)。
  • 药物治疗组少数群体主要事件率远高于非少数群体(27.4% vs 9.4%)。

关键数值与推荐

  • 主要终点为死亡、致残性卒中、严重出血或心脏骤停的复合终点。
  • 少数群体消融组主要终点aHR 0.32(95%CI 0.13-0.78),全因死亡aHR 0.28(95%CI 0.10-0.79)。

临床怎么用

  • 对种族/族裔少数群体症状性房颤患者,导管消融可作为改善主要临床结局的节律控制策略。
  • 该人群药物治疗事件率较高,临床决策时应充分考虑药物治疗的劣势。

局限性

  • 少数群体样本量较小(127例),亚组分析结果需谨慎解读。
  • 本分析仅纳入北美参与者,结论外推至其他地区需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rhythm control strategies for atrial fibrillation (AF), including catheter ablation, are substantially underused in racial/ethnic minorities in North America. OBJECTIVES: This study sought to describe outcomes in the CABANA trial as a function of race/ethnicity. METHODS: CABANA randomized 2,204 symptomatic participants with AF to ablation or drug therapy including rate and/or rhythm control drugs. Only participants in North America were included in the present analysis, and participants were subgrouped as racial/ethnic minority or nonminority with the use of National Institutes of Health definitions. The primary endpoint was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. RESULTS: Of 1,280 participants enrolled in CABANA in North America, 127 (9.9%) were racial and ethnic minorities. Compared with nonminorities, racial and ethnic minorities were younger with median age 65.6 versus 68.5 years, respectively, and had more symptomatic heart failure (37.0% vs 22.0%), hypertension (92.1% vs 76.8%, respectively), and ejection fraction <40% (20.8% vs 7.1%). Racial/ethnic minorities treated with ablation had a 68% relative reduction in the primary endpoint (adjusted hazard ratio [aHR]: 0.32; 95% confidence interval [CI]: 0.13-0.78) and a 72% relative reduction in all-cause mortality (aHR: 0.28; 95% CI: 0.10-0.79). Primary event rates in racial/ethnic minority and nonminority participants were similar in the ablation arm (4-year Kaplan-Meier event rates 12.3% vs 9.9%); however, racial and ethnic minorities randomized to drug therapy had a much higher event rate than nonminority participants (27.4% vs. 9.4%). CONCLUSION: Among racial or ethnic minorities enrolled in the North American CABANA cohort, catheter ablation significantly improved major clinical outcomes compared with drug therapy. These benefits, which were not seen in nonminority participants, appear to be due to worse outcomes with drug therapy. (Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial [CABANA]; NCT00911508).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Thomas KL, Al-Khalidi HR, Silverstein AP, et al. Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities. J Am Coll Cardiol. 2021. PMID: 34238436. doi:10.1016/j.jacc.2021.04.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。